Ironwood Jumps on Phase 2a Data; Ultragenyx Climbs -- Biotech Movers

 | Dec 04, 2017 | 9:29 AM EST
  • Comment
  • Print Print
  • Print
Stock quotes in this article:

irwd

,

rare

,

rarx

Shares of Ironwood Pharmaceuticals Inc.  (IRWD) jumped 3.5% to $17.93 in premarket trading on Monday, Dec. 4, after the Cambridge, Mass.-based firm unveiled top-line data from a pair of Phase 2a studies evaluating IW-1973 in patients that have type 2 diabetes and hypertension.

"Consistent with pre-clinical observations, in both studies treatment with IW-1973 led to blood pressure reductions and improvements in metabolic parameters, including reductions in fasting plasma glucose and cholesterol levels, in patients who were taking a stable regimen of therapies to manage their disease," Ironwood said.

Meanwhile, shares of Ultragenyx Pharmaceutical Inc. (RARE) were up 4.5% to $54 after the Novato, Calif.-based firm, along with Kyowa Hakko Kirin Co. Ltd. and Kyowa Kirin International plc, reported positive 48-week data from a Phase 3 study of burosumab (KRN23) in adults with X-linked hypophosphatemia, a bone disease.

Ultragenyx and Kyowa Hakko Kirin in August 2013 signed a collaboration and license pact to develop and commercialize KRN23.

In other news, Cambridge, Mass.-based Ra Pharmaceuticals Inc. (RARX) unveiled positive interim data from its Phase 2 clinical program on RA101495 SC for the treatment of  blood disorder paroxysmal nocturnal hemoglobinuria. Shares of Ra climbed 1.8% to $14.49 in premarket trading.

 

Columnist Conversations

Facebook had outstanding earnings and looks to continue upward, while HD is a strong breakout on volume and Ak...
Stock picking contests can be entertaining and can provide some interesting ideas but if you seriously want to...
Your Reality Check. Check out Real Money's Helene Meisler's latest podcast here. Subscribe to Meisler's T...
XBTUSD (Bitcoin) On 4/25 Bitcoin top ticked @ 9755.52 and then FELL. Our first short term support @ 8990 was...

BEST IDEAS

REAL MONEY'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.